News
3d
Medpage Today on MSNPrivate Equity in Heart Failure Care; Oral PCSK9 Inhibitor Wins; First Robotic TAVRThe world's first robotic transcatheter aortic valve replacement (TAVR) explant and aortic valve replacement took place at ...
Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and ...
A new method, based on the use of molecules known as polypurine hairpins, facilitates the uptake of cholesterol by cells and ...
When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...
2d
News-Medical.Net on MSNNew therapeutic approach targets PCSK9 to regulate blood cholesterol levelsWhen the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Explore more
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...
9d
News-Medical.Net on MSNPCSK9 protein controls how pancreatic cancer cells spread to the lung or liverA protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.
Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...
Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results